NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Nick, thanks very logical; when was it written.

Also, if ATL or someone else comes up with a comparison table for the new secondary endpoint rGBM like he did for the new Primary endpoint nGBM which is very useful, that would be immensely valuable.

$NWBO: The new #DCVax Phase 3 trial Primary Endpoint is: "compare overall survival between patients randomized to DCVax-L & control patients from comparable, contemporaneous trials who received SOC, in patients with newly diagnosed Glioblastoma". I updated my comparison Table: pic.twitter.com/bzgpUrgN51

— ATLnsider (@ATLnsider) December 13, 2020

I think alphapuppy did a beautiful analysis on the new third and fourth endpoints which were the original Primary and Secondary endpoints that he was predicting a success.

The new endpoints are here
https://knowwhatyouhold.com/uploads/default/original/1X/830ddfb5fcdd8d210b8e8050b4d85d10b5f76dc2.png

My goal here is to perceive how well we might have met all new endpoints.